MDXG News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

MD

Mkt Cap

$647.2M

Volume

2.57M

Next Earnings

October 28th

Loading chart

MD

MDXGMiMedx Group, Inc

MDXG

Pay with—

Available Balance0.00

MD

Mkt Cap

$646.5M

Volume

2.57M

Next Earnings

October 28th

Chart Financials Earnings News About Insider Filings

MIMEDX to Host Third Quarter 2026 Operating and Financial Results Conference Call on October 28, 2026MiMedx Group, Inc. announced it will report Q3 2026 financial results on October 28, 2026, followed by a webcast and conference call at 4:30 p.m. ET. The company also announced a favorable federal court ruling vacating FDA determinations regarding AXIOFILL's regulatory classification as a biological product.GlobeNewswire Inc. · Oct 14, 2026

MIMEDX to Participate in Upcoming Investor ConferencesMIMEDX Group reported second quarter 2026 net sales of $64 million and reiterated its full year financial outlook. The company announced plans to acquire Sanara MedTech in a transformational combination aimed at creating a leading regenerative medicine company and expanding MIMEDX's surgical footprint across multiple surgical subspecialties.GlobeNewswire Inc. · Sep 8, 2026

MIMEDX to Host Fourth Quarter and Full Year 2025 Operating and Financial Results Conference Call on February 25MiMedx Group, Inc. announced it will report its fourth quarter and full year 2025 financial results on February 25, 2026, followed by a webcast and conference call with senior management at 4:30 p.m. Eastern Time to review the results.GlobeNewswire Inc. · Feb 17, 2026

MIMEDX Celebrates 15 Year Anniversary of EPIFIX® and AMNIOFIX®MIMEDX marks the 15th anniversary of its flagship placental allograft products EPIFIX and AMNIOFIX, which have been featured in nearly 100 clinical and scientific publications including seven randomized controlled trials. The company positions these products as the industry's most studied placental allografts, used across multiple surgical specialties for wound care and surgical recovery applications.GlobeNewswire Inc. · Feb 2, 2026

MIMEDX to Host Third Quarter 2025 Operating and Financial Results Conference Call on October 29MiMedx Group will report its third quarter 2025 financial results on October 29, 2025, with a webcast and conference call scheduled for 4:30 p.m. Eastern Time.GlobeNewswire Inc. · Oct 15, 2025

MIMEDX to Sponsor and Attend Symposium on Advanced Wound Care (SAWC) FallMiMedx Group will showcase its advanced wound care portfolio at the Symposium on Advanced Wound Care Fall meeting in Las Vegas, presenting six clinical and scientific posters focused on wound healing technologies and treatments.GlobeNewswire Inc. · Sep 3, 2025

MediWound Initiates the VALUE Global Phase III Pivotal Trial of EscharEx® for Treatment of Venous Leg UlcersMediWound has initiated a global Phase III trial to evaluate the efficacy and safety of its wound debridement therapy EscharEx for the treatment of venous leg ulcers. The trial aims to assess EscharEx's ability to effectively debride chronic wounds and prepare the wound bed for healing.GlobeNewswire Inc. · Feb 12, 2025

Chronic Wound Care Market to Expand at a Modest 4.17% CAGR through 2031 | SkyQuest TechnologyThe chronic wound care market is expected to grow at a CAGR of 4.17% from 2024 to 2031, driven by the high prevalence of chronic diseases and advancements in wound care technologies. The market is segmented by product, application, end-user, and region, with North America leading due to its developed healthcare infrastructure.Benzinga · Nov 26, 2024

MIMEDX Points to The New York Times Article on the Vast Benefits of Placental TissueThe article highlights the benefits of placental allografts for wound care and surgical procedures, featuring two individuals who had successful recoveries using MIMEDX's products. The article is expected to increase awareness about the unique properties and growing clinical use of placental-derived products.GlobeNewswire Inc. · Oct 8, 2024

MIMEDX Showcases Leading Allograft Portfolio and Its Latest Scientific and Clinical Evidence at SAWC FallMIMEDX, a leader in wound care products, is showcasing its latest research and clinical evidence at the Symposium on Advanced Wound Care (SAWC) Fall meeting. The company is sponsoring a lunch symposium and a hands-on skills lab, and has seven accepted posters on various topics related to wound healing.GlobeNewswire Inc. · Oct 1, 2024

to start trading

MD

MDXGMiMedx Group, Inc

MDXG

Pay with—

Available Balance0.00

Your PositionYou don't own any MDXG yet.

Related Tickers

Earnings